{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:11:38Z","timestamp":1781712698036,"version":"3.54.5"},"reference-count":81,"publisher":"Elsevier","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.irn.2025.04.027","type":"book-chapter","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T11:14:57Z","timestamp":1748430897000},"source":"Crossref","is-referenced-by-count":3,"title":["Lambert Eaton Myasthenic Syndrome"],"prefix":"10.1016","author":[{"given":"Shadi","family":"El-Wahsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Reddel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/bs.irn.2025.04.027_bib1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/mus.25520","article-title":"Lambert\u2013Eaton myasthenic syndrome: Epidemiology and therapeutic response in the national veterans affairs population","volume":"56","author":"Abenroth","year":"2017","journal-title":"Muscle & Nerve"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.027_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21926\/obm.neurobiol.2101086","article-title":"Case report of Lambert Eaton myasthenic syndrome in a patient with small cell lung cancer on immune checkpoint inhibitor therapy","volume":"5","author":"Anderson","year":"2021","journal-title":"OBM Neurobiology"},{"issue":"7","key":"10.1016\/bs.irn.2025.04.027_bib3","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/mus.880180707","article-title":"Lambert\u2014Eaton myasthenic syndrome (LEMS) in association with lymphoproliferative disorders","volume":"18","author":"Argov","year":"1995","journal-title":"Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.027_bib4","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/WNL.47.3.678","article-title":"Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome","volume":"47","author":"Bain","year":"1996","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.027_bib5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0165-5728(00)00431-8","article-title":"Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line","volume":"113","author":"Benatar","year":"2001","journal-title":"Journal of Neuroimmunology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.027_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1445-5994.1973.tb03959.x","article-title":"Implications of cancer immunity","volume":"3","author":"Burnet","year":"1973","journal-title":"Australian and New Zealand Journal of Medicine"},{"key":"10.1016\/bs.irn.2025.04.027_bib7","series-title":"Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3, 4\u2010diaminopyridine","first-page":"165","author":"Burns","year":"2016"},{"issue":"10","key":"10.1016\/bs.irn.2025.04.027_bib8","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1212\/WNL.42.10.1944","article-title":"Paraneoplastic cerebellar degeneration: III. Cerebellar degeneration, cancer, and the Lambert\u2010Eaton myasthenic syndrome","volume":"42","author":"Clouston","year":"1992","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.027_bib9","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/ana.410110604","article-title":"Plasmapheresis and immunosuppressive drug therapy in the Eaton\u2010Lambert syndrome","volume":"11","author":"Dau","year":"1982","journal-title":"Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.027_bib10","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1002\/j.2040-4603.2022.tb00230.x","article-title":"Structure and function of the mammalian neuromuscular junction","volume":"12","author":"Davis","year":"2022","journal-title":"Comprehensive Physiology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.027_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/mus.25046","article-title":"Clinical significance of cation channel antibodies in motor neuron disease","volume":"54","author":"Donaldson","year":"2016","journal-title":"Muscle & Nerve"},{"issue":"13","key":"10.1016\/bs.irn.2025.04.027_bib12","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1001\/jama.1957.02970480021005","article-title":"Electromyography and electric stimulation of nerves in diseases of motor unit: observations on myasthenic syndrome associated with malignant tumors","volume":"163","author":"Eaton","year":"1957","journal-title":"Journal of the American Medical Association"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.027_bib13","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1113\/jphysiol.2002.021048","article-title":"Passive transfer of Lambert\u2010Eaton syndrome to mice induces dihydropyridine sensitivity of neuromuscular transmission","volume":"543","author":"Flink","year":"2002","journal-title":"The Journal of Physiology"},{"issue":"24","key":"10.1016\/bs.irn.2025.04.027_bib14","doi-asserted-by":"crossref","first-page":"7636","DOI":"10.1073\/pnas.80.24.7636","article-title":"Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones","volume":"80","author":"Fukunaga","year":"1983","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.027_bib15","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1152\/jn.00404.2022","article-title":"Simulations of active zone structure and function at mammalian NMJs predict that loss of calcium channels alone is not sufficient to replicate LEMS effects","volume":"129","author":"Ginebaugh","year":"2023","journal-title":"Journal of Neurophysiology"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.027_bib16","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1212\/WNL.59.5.764","article-title":"P\/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer","volume":"59","author":"Graus","year":"2002","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.027_bib17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/mus.24295","article-title":"Lambert\u2013Eaton syndrome antibodies target multiple subunits of voltage\u2010gated Ca2+ channels","volume":"51","author":"Hajela","year":"2015","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.027_bib18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/978-3-319-73585-6_14","article-title":"Lambert-Eaton syndrome","author":"Harper","year":"2018","journal-title":"Myasthenia Gravis and Related Disorders"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.027_bib19","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/mus.20979","article-title":"Ten\u2010second exercise is superior to 30\u2010second exercise for post\u2010exercise facilitation in diagnosing Lambert\u2013Eaton myasthenic syndrome","volume":"37","author":"Hatanaka","year":"2008","journal-title":"Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine"},{"key":"10.1016\/bs.irn.2025.04.027_bib20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.msard.2018.10.015","article-title":"Lambert\u2013Eaton myasthenic syndrome associated with alemtuzumab administration","volume":"27","author":"Hoffman","year":"2019","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"9","key":"10.1016\/bs.irn.2025.04.027_bib21","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/j.1460-9568.2010.07430.x","article-title":"Kinetics of acetylcholine quanta release at the neuromuscular junction during high\u2010frequency nerve stimulation","volume":"32","author":"Kovyazina","year":"2010","journal-title":"European Journal of Neuroscience"},{"issue":"11","key":"10.1016\/bs.irn.2025.04.027_bib22","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/mus.880111105","article-title":"Selected IgG rapidly induces Lambert\u2013Eaton myasthenic syndrome in mice: Complement independence and EMG abnormalities","volume":"11","author":"Lambert","year":"1988","journal-title":"Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine"},{"issue":"8240","key":"10.1016\/bs.irn.2025.04.027_bib23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0140-6736(81)90474-8","article-title":"Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome","volume":"318","author":"Lang","year":"1981","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.027_bib24","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1212\/WNL.30.6.634","article-title":"Eaton\u2010Lambert syndrome and malignant thymoma","volume":"30","author":"Lauritzen","year":"1980","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/bs.irn.2025.04.027_bib25","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","article-title":"Calcium-channel antibodies in the Lambert\u2013Eaton syndrome and other paraneoplastic syndromes","volume":"332","author":"Lennon","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.027_bib26","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1212\/WNL.0000000000008747","article-title":"Long\u2010term follow\u2010up, quality of life, and survival of patients with Lambert\u2010Eaton myasthenic syndrome","volume":"94","author":"Lipka","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.027_bib27","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/syn.890010402","article-title":"Calcium\u2010Insensitive miniature endplate potentials at the neuromuscular junction","volume":"1","author":"Lupa","year":"1987","journal-title":"Synapse (New York, N. Y.)"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.027_bib28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1152\/jn.00198.2014","article-title":"New insights into short-term synaptic facilitation at the frog neuromuscular junction","volume":"113","author":"Ma","year":"2015","journal-title":"Journal of Neurophysiology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.027_bib29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.14740\/jmc4043","article-title":"Durvalumab for extensive-stage of small-cell lung cancer with lambert-eaton myasthenic syndrome","volume":"14","author":"Machiyama","year":"2023","journal-title":"Journal of Medical Cases"},{"issue":"14","key":"10.1016\/bs.irn.2025.04.027_bib30","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1212\/WNL.0000000000003794","article-title":"Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome","volume":"88","author":"Maddison","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.027_bib31","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/jnnp.70.2.212","article-title":"Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer","volume":"70","author":"Maddison","year":"2001","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.027_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-67571-9","article-title":"Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort","volume":"10","author":"Maddison","year":"2020","journal-title":"Scientific Reports"},{"issue":"9147","key":"10.1016\/bs.irn.2025.04.027_bib33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(05)76153-5","article-title":"Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma","volume":"353","author":"Maddison","year":"1999","journal-title":"The Lancet"},{"issue":"12","key":"10.1016\/bs.irn.2025.04.027_bib34","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1212\/01.WNL.0000099748.41130.9A","article-title":"Presynaptic failure of neuromuscular transmission and synaptic remodeling in EA2","volume":"61","author":"Maselli","year":"2003","journal-title":"Neurology"},{"issue":"23","key":"10.1016\/bs.irn.2025.04.027_bib35","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","article-title":"3, 4-Diaminopyridine in the treatment of Lambert\u2013Eaton myasthenic syndrome","volume":"321","author":"McEvoy","year":"1989","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.027_bib36","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/archneurol.2009.336","article-title":"Positron emission tomography\u2013computed tomography in paraneoplastic neurologic disorders: Systematic analysis and review","volume":"67","author":"McKeon","year":"2010","journal-title":"Archives of Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.027_bib37","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s40120-022-00354-8","article-title":"The European Lambert\u2013Eaton myasthenic syndrome registry: Long-term outcomes following symptomatic treatment","volume":"11","author":"Meisel","year":"2022","journal-title":"Neurology and Therapy"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.027_bib38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-510X(96)05303-8","article-title":"Incidence of serum anti-P\/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome","volume":"147","author":"Motomura","year":"1997","journal-title":"Journal of the Neurological Sciences"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.027_bib39","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000494078","article-title":"Lambert-Eaton myasthenic syndrome caused by nivolumab in a patient with squamous cell lung cancer","volume":"10","author":"Nakatani","year":"2019","journal-title":"Case Reports in Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.027_bib40","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/mus.25208","article-title":"Effect of 3, 4\u2010diaminopyridine at the murine neuromuscular junction","volume":"55","author":"Ng","year":"2017","journal-title":"Muscle & Nerve"},{"issue":"7","key":"10.1016\/bs.irn.2025.04.027_bib41","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1212\/WNL.59.7.1085","article-title":"Postexercise facilitation of reflexes is not common in Lambert\u2013Eaton myasthenic syndrome","volume":"59","author":"Odabasi","year":"2002","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.027_bib42","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/mus.880120605","article-title":"Diverse electrophysiological spectrum of the Lambert\u2013Eaton myasthenic syndrome","volume":"12","author":"Oh","year":"1989","journal-title":"Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.027_bib43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/mus.24921","article-title":"Myasthenia gravis Lambert\u2010Eaton overlap syndrome","volume":"53","author":"Oh","year":"2016","journal-title":"Muscle & Nerve"},{"issue":"10","key":"10.1016\/bs.irn.2025.04.027_bib44","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/1744666X.2020.1670061","article-title":"Amifampridine for the treatment of Lambert-Eaton myasthenic syndrome","volume":"15","author":"Oh","year":"2019","journal-title":"Expert Review of Clinical Immunology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.027_bib45","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/mus.20672","article-title":"Electrophysiological differences in seropositive and seronegative Lambert\u2013Eaton myasthenic syndrome","volume":"35","author":"Oh","year":"2007","journal-title":"Muscle & Nerve"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.027_bib46","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/mus.20389","article-title":"Electrophysiological diagnostic criteria of Lambert\u2013Eaton myasthenic syndrome","volume":"32","author":"Oh","year":"2005","journal-title":"Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.027_bib47","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/mus.23638","article-title":"Single\u2010fiber EMG and clinical correlation in Lambert\u2010Eaton myasthenic syndrome","volume":"47","author":"Oh","year":"2013","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.027_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100302","article-title":"A high-affinity, partial antagonist effect of 3, 4-diaminopyridine mediates action potential broadening and enhancement of transmitter release at NMJs","volume":"296","author":"Ojala","year":"2021","journal-title":"Journal of Biological Chemistry"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.027_bib49","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/brain\/111.3.577","article-title":"The Lambert-Eaton myasthenic syndrome: A review of 50 cases","volume":"111","author":"O'neill","year":"1988","journal-title":"Brain"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.027_bib50","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/JTO.0b013e3181c3f4f1","article-title":"Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer","volume":"5","author":"Payne","year":"2010","journal-title":"Journal of Thoracic Oncology"},{"issue":"1-2","key":"10.1016\/bs.irn.2025.04.027_bib51","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jneuroim.2009.09.017","article-title":"Managing non-paraneoplastic Lambert\u2013Eaton myasthenic syndrome: Clinical characteristics in 25 German patients","volume":"217","author":"Pellkofer","year":"2009","journal-title":"Journal of Neuroimmunology"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.027_bib52","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/mus.10087","article-title":"The action of Lambert\u2013Eaton myasthenic syndrome immunoglobulin G on cloned human voltage\u2010gated calcium channels","volume":"25","author":"Pinto","year":"2002","journal-title":"Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.027_bib53","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3233\/JND-221646","article-title":"Presynaptic congenital myasthenic syndromes: Understanding clinical phenotypes through in vivo models","volume":"10","author":"Pugliese","year":"2023","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"21","key":"10.1016\/bs.irn.2025.04.027_bib54","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000264798.56174.df","article-title":"Lambert-Eaton myasthenic syndrome with pure ocular weakness","volume":"68","author":"Rudnicki","year":"2007","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/bs.irn.2025.04.027_bib55","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1212\/01.wnl.0000281663.81079.24","article-title":"SOX1 antibodies are markers of paraneoplastic Lambert\u2013Eaton myasthenic syndrome","volume":"70","author":"Sabater","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.027_bib56","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3389\/fonc.2020.01074","article-title":"Update on the biology, management, and treatment of small cell lung cancer (SCLC)","volume":"10","author":"Saltos","year":"2020","journal-title":"Frontiers in Oncology"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.027_bib57","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.clinph.2013.11.007","article-title":"Is the decremental pattern in Lambert\u2013Eaton syndrome different from that in myasthenia gravis?","volume":"125","author":"Sanders","year":"2014","journal-title":"Clinical Neurophysiology"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.027_bib58","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/mus.27794","article-title":"The duke myasthenia gravis clinic registry: II. Analysis of outcomes","volume":"67","author":"Sanders","year":"2023","journal-title":"Muscle & Nerve"},{"issue":"8664","key":"10.1016\/bs.irn.2025.04.027_bib59","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0140-6736(89)90893-3","article-title":"Specificity of calcium channel autoantibodies in Lambert-Eaton myasthenic syndrome","volume":"334","author":"Sher","year":"1989","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.027_bib60","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.46.4.1143","article-title":"Acute ventilatory failure in Lambert-Eaton myasthenic syndrome and its response to 3, 4-diaminopyridine","volume":"46","author":"Smith","year":"1996","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/bs.irn.2025.04.027_bib61","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1113\/jphysiol.2014.276493","article-title":"Complete reversal of Lambert\u2013Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist","volume":"592","author":"Tarr","year":"2014","journal-title":"The Journal of Physiology"},{"key":"10.1016\/bs.irn.2025.04.027_bib62","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s12035-014-8887-2","article-title":"Synaptic pathophysiology and treatment of Lambert-Eaton myasthenic syndrome","volume":"52","author":"Tarr","year":"2015","journal-title":"Molecular Neurobiology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.027_bib63","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1749-6632.1998.tb11024.x","article-title":"Lambert\u2010Eaton myasthenic syndrome (LEMS): Clinical and electrodiagnostic features and response to therapy in 59 patients","volume":"841","author":"Tim","year":"1998","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"11","key":"10.1016\/bs.irn.2025.04.027_bib64","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1212\/WNL.54.11.2176","article-title":"Lambert-Eaton myasthenic syndrome: Electrodiagnostic findings and response to treatment","volume":"54","author":"Tim","year":"2000","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.027_bib65","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1468-1331.2010.03220.x","article-title":"Screening for tumours in paraneoplastic syndromes: report of an EFNS task force","volume":"18","author":"Titulaer","year":"2011","journal-title":"European Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.04.027_bib66","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jneuroim.2008.05.025","article-title":"The Lambert\u2013Eaton myasthenic syndrome 1988\u20132008: A clinical picture in 97 patients","volume":"201","author":"Titulaer","year":"2008","journal-title":"Journal of Neuroimmunology"},{"issue":"26","key":"10.1016\/bs.irn.2025.04.027_bib67","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1200\/JCO.2008.20.6169","article-title":"SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: Frequency and relation with survival","volume":"27","author":"Titulaer","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1016\/bs.irn.2025.04.027_bib68","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","article-title":"Lambert\u2013Eaton myasthenic syndrome: From clinical characteristics to therapeutic strategies","volume":"10","author":"Titulaer","year":"2011","journal-title":"The Lancet Neurology"},{"issue":"7","key":"10.1016\/bs.irn.2025.04.027_bib69","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1200\/JCO.2010.32.0440","article-title":"Clinical Dutch-English Lambert-Eaton myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS","volume":"29","author":"Titulaer","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.027_bib70","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1196\/annals.1405.030","article-title":"Lambert\u2013Eaton myasthenic syndrome: Tumor versus nontumor forms","volume":"1132","author":"Titulaer","year":"2008","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"26","key":"10.1016\/bs.irn.2025.04.027_bib71","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1200\/JCO.2008.17.5133","article-title":"Screening for small-cell lung cancer: A follow-up study of patients with Lambert-Eaton myasthenic syndrome","volume":"26","author":"Titulaer","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.irn.2025.04.027_bib72","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cnp.2018.07.001","article-title":"Stimulated single-fiber electromyography (sSFEMG) in Lambert-Eaton syndrome","volume":"3","author":"Todisco","year":"2018","journal-title":"Clinical Neurophysiology Practice"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.027_bib73","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/mus.21301","article-title":"\u201cDropped head syndrome\u201d caused by Lambert\u2013Eaton myasthenic syndrome","volume":"40","author":"Ueda","year":"2009","journal-title":"Muscle & Nerve"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.027_bib74","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF02329922","article-title":"Autonomic dysfunction in Lambert-Eaton myasthenic syndrome","volume":"11","author":"Waterman","year":"2001","journal-title":"Clinical Autonomic Research"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.027_bib75","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/ana.410420204","article-title":"Effect of Lambert\u2010Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse","volume":"42","author":"Waterman","year":"1997","journal-title":"Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.027_bib76","doi-asserted-by":"crossref","first-page":"C31","DOI":"10.1152\/ajpcell.1979.237.1.C31","article-title":"Depression, facilitation, and mobilization of transmitter at the rat diaphragm neuromuscular junction","volume":"237","author":"Wilson","year":"1979","journal-title":"American Journal of Physiology-Cell Physiology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.027_bib77","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/clpt.2009.35","article-title":"Efficacy of 3, 4\u2010diaminopyridine and pyridostigmine in the treatment of Lambert\u2013Eaton myasthenic syndrome: A randomized, double\u2010blind, placebo\u2010controlled, crossover study","volume":"86","author":"Wirtz","year":"2009","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/bs.irn.2025.04.027_bib78","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00415-004-0528-7","article-title":"Associated autoimmune diseases in patients with the Lambert-Eaton myasthenic syndrome and their families","volume":"251","author":"Wirtz","year":"2004","journal-title":"Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.04.027_bib79","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s00415-003-1063-7","article-title":"The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland","volume":"250","author":"Wirtz","year":"2003","journal-title":"Journal of Neurology"},{"issue":"1-2","key":"10.1016\/bs.irn.2025.04.027_bib80","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jneuroim.2004.10.018","article-title":"HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert\u2013Eaton myasthenic syndrome","volume":"159","author":"Wirtz","year":"2005","journal-title":"Journal of Neuroimmunology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.027_bib81","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/WNO.0000000000000258","article-title":"Lambert\u2013Eaton myasthenic syndrome: Ocular signs and symptoms","volume":"36","author":"Young","year":"2016","journal-title":"Journal of Neuro-Ophthalmology"}],"container-title":["International Review of Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S007477422500042X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S007477422500042X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T11:15:11Z","timestamp":1748430911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S007477422500042X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":81,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2025.04.027","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}